Lundbeck to test Vyepti in direct comparison with competitors

In a new phase IV real-world study, Lundbeck will test how well migraine infusion Vyepti does compared to other therapies of the same class.

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

200 people in the US will help shed light on how well the newest generation of migraine therapies perform in a direct comparison of their preventive effects on migraine episodes.

Danish pharmaceutical firm Lundbeck is behind the study, having initiated recruitment in March for a phase IV trial comparing its own Vyepti (eptinezumab) to the Amgen/Novartis drug, Aimovig (erenumab), Teva’s Ajovy (fremanezumab), Eli Lilly’s Emgality (galcanezumab), as well as Botox in its migraine formulation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs